Evaluation of the Effect of the First Generation iStent on Corneal Endothelial Cell Loss—A Match Case-Control Study
Open Access
- 26 September 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (19) , 4410
Abstract
Glaucoma is the leading cause of irreversible blindness worldwide. The only proven factor in slowing the progression of glaucomatous neuropathy is lower intraocular pressure (IOP), which can be achieved with pharmacology, laser therapy, or surgery. However, these treatments are associated with various adverse effects, including corneal endothelial cell loss (CECL). In recent years, several novel surgeries for reducing the IOP, collectively referred to as minimally invasive glaucoma surgery (MIGS), have been developed, one of which is the iStent. However, the long-term effects of such surgeries remain unknown. We compared a group of patients with open-angle glaucoma and cataract who underwent phacoemulsification alone with a group of patients with similar demographic and clinical characteristics who underwent simultaneous phacoemulsification and iStent implantation. Overall, 26 eyes of 22 subjects who underwent a combined phacoemulsification-iStent procedure and 26 eyes of 24 subjects who underwent cataract surgery were included. Before surgery, endothelial cells accounted to 2228.65 ± 474.99 in iStent group and 2253.96 ± 404.76 in the control group (p = 0.836). After surgery, their number declined to 1389.77 ± 433.26 and 1475.31 ± 556.45, respectively (p = 0.509). There was no statistically significant difference in CECL between the two groups 18–24 months after surgery, despite increased manipulation in the anterior chamber and the presence of an implant in the trabecular meshwork in those with an iStent implant. Thus, iStent bypass implantation is a safe treatment in terms of CECL for mild-to-moderate open-angle glaucoma.Keywords
This publication has 36 references indexed in Scilit:
- Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucomaClinical Ophthalmology, 2014
- Prospective, Unmasked Evaluation of the iStent® Inject System for Open-Angle Glaucoma: Synergy TrialAdvances in Therapy, 2014
- Effect on corneal endothelial cell loss during phacoemulsification: Fortified balanced salt solution versus Ringer lactateJournal of Cataract & Refractive Surgery, 2012
- Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term studyBritish Journal of Ophthalmology, 2012
- Corneal Endothelial Cell Changes After Ahmed ™ Valve and Molteno ™ Glaucoma ImplantsOphthalmic Surgery, Lasers and Imaging Retina, 2011
- Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucomaJournal of Cataract & Refractive Surgery, 2010
- Changes in corneal endothelial cell density and morphology after Ahmed glaucoma valve implantation during the first year of follow upClinical & Experimental Ophthalmology, 2008
- Factors related to corneal endothelial damage after phacoemulsification in eyes with occludable anglesJournal of Cataract & Refractive Surgery, 2008
- Long-term endothelial cell loss following phacoemulsification through a temporal clear corneal incisionJournal of Cataract & Refractive Surgery, 1996
- Advanced Glaucoma Intervention StudyOphthalmology, 1994